Showing 2921-2930 of 5771 results for "".
- ViaLase and the John A. Moran Eye Center Partner to Accelerate Glaucoma Research and Innovationhttps://modernod.com/news/vialase-and-the-john-a-moran-eye-center-announce-research-partnership-to-accelerate-glaucoma-research-and-innovation/2482573/ViaLase announced a research partnership with the John A. Moran Eye Center at the University of Utah, home to the Alan S. Crandall Center for Glaucoma Innovation. The collaboration will explore aqueous outflow dynamics of ViaLase’s ViaLase laser procedure, utilizing Moran’s iPerf
- OneSight EssilorLuxottica Foundation Partners with WHO on SPECS 2030 Initiativehttps://modernod.com/news/onesight-essilorluxottica-foundation-partners-with-who-on-specs-2030-initiative-1/2482570/The OneSight EssilorLuxottica Foundation has announced a collaboration with the World Health Organization (WHO) as a global partner in the SPECS 2030 initiative. This strategic alliance is set to accelerate progress toward the world’s first global target for effective refractive error cover
- Galimedix Begins Phase 1 Clinical Trial of Oral GAL-101 for Neuroprotective Treatmenthttps://modernod.com/news/galimedix-therapeutics-begins-phase-1-clinical-trial-of-oral-gal-101-for-neuroprotective-treatment/2482565/Galimedix Therapeutics announced the first volunteers have been dosed in the company’s phase 1 study of oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses
- Ophthalmic Industry Veteran Scott Hunter Passes Awayhttps://modernod.com/news/ophthalmic-industry-veteran-scott-hunter-passes-away/2482564/Longtime ophthalmic industry leader Scott Hunter passed away on December 3, Neurotech announced. Mr. Hunter was the Chief Commercial Officer of Neurotech, a position he held since January 2023. “The entire Neurotech family mourns this loss. On behalf of the Board of Directors, man
- Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in Chinahttps://modernod.com/news/nicoxs-denali-phase-3-trial-of-ncx-470-fully-enrolled-in-china/2482561/Nicox announced that its Denali phase 3 trial evaluating the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension is now fully enrolled in China and screening has been closed. Completion of recruitment of patients in the
- Nidek Launches NP-T Preloaded Toric IOL Injection Systemhttps://modernod.com/news/nidek-launches-np-t-preloaded-toric-iol-injection-system/2482560/Nidek announced the international launch of its NP-T Preloaded Toric IOL Injection System. Previously available exclusively in Japan, the system is now available globally. The NP-T system is designed to combine precision engineering with user-friendly design, featuring a prelo
- FDA Clears Novoxel's Tixel for the Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/fda-clears-novoxels-tixel-for-the-treatment-of-meibomian-gland-dysfunction/2482559/Isreal-based Novoxel announced the the FDA clearance of its Tixel device for application of localized heat and pressure for patients with evaporative dry eye due to meibomian gland dysfunction (MGD). The Tixel systems use proprietary Thermo-Mechanical Actio
- Johnson & Johnson Appoints Shawn Millerick President, Vision Care, Americashttps://modernod.com/news/johnson-johnson-appoints-shawn-millerick-president-vision-care-americas/2482556/Johnson & Johnsonhas announced the appointment of Shawn Millerick as President, Vision Care, Americas, effective November 11, 2024. Mr. Millerick will be responsible for defining strategy and driving growth for Johnson & Johnson’s Vision Care portfolio in North Americ
- BostonSight Publishes Study Highlighting Prose Lens Utilization for Drug Deliveryhttps://modernod.com/news/bostonsight-publishes-study-highlighting-prose-lens-utilization-for-drug-delivery/2482555/BostonSight announced it has published a study: “
- Alcon Expands TOTAL30 for Astigmatism Offerings with New Parametershttps://modernod.com/news/alcon-expands-total30-for-astigmatism-offerings-with-new-parameters-to-enhance-comfort-and-accessibility/2482553/Alcon announced the availability of expanded parameters for TOTAL30 for Astigmatism. As the first and only monthly replacement Water Gradient toric contact lens, TOTAL30 is designed to deliver a